NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies Holdings (NTHI) CEO Amir F. Heshmatpour purchased 37,000 additional common shares on September 11, 2026, after a recently announced $15 million institutional financing.
The Form 4 filing shows a weighted-average purchase price of $3.6654 per share, or about $135,620, continuing his pattern of insider buying. The $15 million financing with healthcare-focused institutional investors, announced September 9, was priced at $4.20 per common share and accompanying warrant, covering about 3.57 million shares or equivalents plus five-year warrants for another 3.57 million shares at a $4.20 exercise price. Net proceeds are intended for working capital, general corporate purposes and redemption of Series A convertible preferred stock.
NeOnc is advancing brain cancer candidates NEO100 and NEO212 under a patented platform licensed from the University of Southern California, with patent protection reported through 2038 and early-stage clinical data guiding its FDA discussions.
NeOnc Technologies Holdings (NTHI) highlighted recent insider share purchases and progress of its NEO100 program toward the next regulatory step as of September 14, 2026. CEO, President and director Amir F. Heshmatpour bought 37,000 NTHI shares at $3.6654 each, an outlay of about $136,000, after the company announced a $15 million registered direct offering at $4.20 per share.
NeOnc reported topline Phase 2a data for NEO100 in recurrent IDH1‑mutant high‑grade glioma, with a 48.9% six‑month progression‑free survival rate versus a pre‑specified 20% benchmark and a 26.09‑month median overall survival. Five of 24 patients remained on treatment at data cutoff. The company plans to request a Type B FDA meeting to discuss a potential registrational path for NEO100 while it continues to advance NEO100 and NEO212 and pursue additional clinical and regulatory milestones.
NeOnc Technologies Holdings (NTHI) announced a $15 million registered direct offering priced at-the-market under Nasdaq rules, involving new and existing healthcare-focused institutional investors.
The deal covers 3.57 million shares, or pre-funded warrants in lieu of shares, plus warrants for another 3.57 million shares with a $4.20 exercise price, with closing expected tomorrow subject to customary conditions. The company highlights that this structure provides capital without a headline discount to market price. The financing coincides with positive NEO100 Phase 2a data in recurrent or progressive Grade III/IV IDH1-mutant glioma, where 6‑month progression-free survival reached 48.9% versus a 20% prespecified benchmark (p=0.0047), median overall survival was 26.09 months, and 86.7% of patients were alive at six months. NeOnc plans to seek a Type B FDA meeting on a potential registrational pathway and reports ongoing NEO212 development and recent insider share purchases by its CEO and a director.
NeOnc Technologies Holdings (NTHI) priced a $15 million registered direct equity offering with institutional investors on September 9, 2026.
The company entered definitive agreements with new and existing healthcare-focused institutional investors to sell 3,571,430 shares of common stock, or pre-funded warrants in lieu thereof, plus accompanying warrants to purchase up to 3,571,430 shares. The combined purchase price is $4.20 per share and warrant, or $4.1999 per pre-funded warrant and warrant. Pre-funded warrants are exercisable immediately at $0.0001 per share and expire when fully exercised, while the accompanying warrants are immediately exercisable at $4.20 per share and expire five years from issuance.
Gross proceeds are estimated at approximately $15 million before fees and expenses, with closing expected on or about September 10, 2026, subject to customary conditions. The securities are offered under NeOnc’s effective Form S-3 shelf registration statement, with Roth Capital Partners and A.G.P./Alliance Global Partners acting as co-placement agents.
NeOnc Technologies (NTHI) reported positive topline Phase 2a data for NEO100 in recurrent or progressive Grade III/IV IDH1-mutant glioma and is planning a Type B FDA meeting to discuss a potential registrational pathway.
The study showed six-month progression-free survival of 48.9%, more than double the prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 86.7% of patients were alive at six months. Five of 24 patients remained on treatment, including one partial response lasting beyond 114 days. NeOnc describes NEO100 as an intranasal, nose-to-brain formulation of purified perillyl alcohol aimed at aggressive gliomas where options are limited.
Beyond the U.S. program, NeOnc received UAE IND authorization for NEO100 across three adult trials and pediatric work, and NEO212 secured UAE IND clearance with a recommended Phase 2 dose of 610 mg. SEC filings show August insider share purchases by director Thomas Chen and CEO Amir Heshmatpour.
NeOnc Technologies Holdings (NASDAQ: NTHI) reported positive topline Phase 2a results for NEO100 in recurrent or progressive Grade III/IV IDH1‑mutant glioma, with six‑month progression‑free survival of 48.9%, substantially above the prespecified 20% benchmark (p=0.0047). Median overall survival was 26.09 months, and 86.7% of patients were alive at six months; five of 24 patients remained on treatment, including one ongoing partial response beyond 114 days.
According to NeOnc, these open‑label Phase 2a data achieved the primary endpoint and will support a planned request for a Type B FDA meeting to discuss a potential registrational pathway for NEO100. The company is also advancing NEO212, which has completed Phase 1 with a recommended Phase 2 dose of 610 mg, and has received UAE IND approvals for NEO100 and NEO212 across several adult and pediatric programs. Recent insider open‑market share purchases by the CEO and a director add to the backdrop as NeOnc remains a clinical‑stage biotech facing the usual development, regulatory and financing risks.
NeOnc Technologies Holdings (NASDAQ: NTHI) highlighted positive topline Phase 2a data for NEO100 in recurrent or progressive Grade III/IV IDH1‑mutant glioma. The study met its primary endpoint, with 48.9% six‑month progression‑free survival versus a prespecified 20% benchmark and a reported p‑value of 0.0047. Median overall survival was 26.09 months, with 86.7% of patients alive at six months; five of 24 patients remained on treatment, including one partial response beyond 114 days. NeOnc reported no major toxicities and predominantly low‑grade adverse events. The company plans to request a Type B FDA meeting to discuss a potential registrational pathway. NeOnc is also advancing NEO212, which completed Phase 1 with a recommended Phase 2 dose of 610 mg, and has obtained UAE IND approvals for NEO100 and NEO212. Insider purchases by the CEO and a board director followed the data, while Nasdaq reported 597,816 NTHI shares sold short as of August 14, 2026.
NeOnc Technologies (NASDAQ:NTHI) is drawing attention after CEO Amir Heshmatpour reported additional open‑market share purchases following a key clinical readout. Form 4 data show he bought 12,000 shares on August 14, 2026 at an average price of $3.7883 and 3,000 shares on August 17 at $4.3733, totaling 15,000 shares for about $58,600 at a roughly $3.91 weighted average. In April, NeOnc had disclosed that he purchased about $500,000 of NTHI stock.
According to NeOnc, NEO100’s Phase 2a study in recurrent IDH1‑mutant high‑grade glioma achieved six‑month progression‑free survival of 48.9% versus a 20% historical benchmark (p=0.0047), with median overall survival of 26.09 months and six‑, 12‑ and 24‑month overall survival rates of 86.7%, 60.9% and 54.1%. NEO100 already has FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations, and the company intends to seek a Type B FDA meeting on a potential registrational path. NeOnc also reports UAE IND authorization for multiple NEO100 protocols and completion of Phase 1 for NEO212 with a recommended Phase 2 dose of 610 mg. The article notes elevated short interest in NTHI, framing a setup that combines insider accumulation, clinical data and significant short positioning.
NeOnc Technologies Holdings (Nasdaq: NTHI) highlighted how its Nasdaq Global Market listing interacts with new Phase 2a data for lead candidate NEO100 in recurrent IDH1‑mutant high‑grade glioma. The company reported a six‑month progression‑free survival rate of 48.9% versus a 20% historical benchmark (p=0.0047), median overall survival of about 26.1 months, and six‑, 12‑ and 24‑month overall‑survival rates of approximately 86.7%, 60.9% and 54.1%, respectively, with no major toxicities reported.
According to NeOnc, the open‑label, single‑arm Phase 2a study provides an encouraging clinical signal but not definitive proof of efficacy, making a larger registrational trial and FDA discussions the next focus. The company emphasized its existing $75 million at‑the‑market equity facility with BTIG and A.G.P./Alliance Global Partners as a flexible financing tool, not cash already on the balance sheet. NeOnc also noted second‑quarter R&D expense of approximately $2.6 million, up from about $0.7 million a year earlier, and referenced additional pipeline work on NEO212 and UAE IND approvals for both NEO100 and NEO212.
NeOnc Technologies (NASDAQ: NTHI) received an updated coverage report highlighting stronger clinical and regulatory positioning in 2Q26. Lead asset NEO100 achieved its Phase 2a primary endpoint, with six‑month PFS of 48.9% by RANO 2.0 versus a 20% benchmark (p=0.0047), median OS of 26.09 months, and no major toxicities. The company plans to seek an FDA Type B meeting to discuss a potential registrational program. NEO212 advanced through Phase 2 CMC clearance and FDA feedback indicating a possible accelerated approval pathway. R&D expenses rose to $2.6M from $0.7M year over year, while management expands development into meningioma and pediatric brain tumors, noting that funding remains important as activity increases.